Form 4: Inhibrx Biosciences CEO Mark Lappe Increases Stake in Company
SEC Form 4 Filing
Inhibrx Biosciences CEO Mark Lappe recently purchased additional shares of the company's common stock through indirect holdings.
Summary
- Mark Lappe, CEO of Inhibrx Biosciences, has reported changes in his beneficial ownership of the company's stock.
- On August 20, 2024, Lappe indirectly acquired 27,055 shares of common stock at a weighted average price of $12.97 through The Mark Paul Lappe Roth IRA.
- On August 21, 2024, he indirectly acquired another 12,945 shares at a weighted average price of $12.93 through the same Roth IRA.
- Following these transactions, Lappe's indirect holdings include 54,865 shares through The Mark Paul Lappe Roth IRA, 621,548 shares through the Lappe Family Trust, and 125,000 shares through another trust for the benefit of his immediate family.
- The reported prices for the August 20 and 21 transactions reflect weighted averages of multiple purchases made at slightly varying prices within the specified ranges.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The CEO's purchase of shares suggests confidence, but it's a routine transaction.
Positives
- The CEO's increased investment in the company may signal confidence in its future prospects.
Industry Context
Insider transactions are closely monitored by investors as they can provide insights into management's perspective on the company's valuation and future performance.
Stakeholder Impact
- Shareholders may view the CEO's increased stake as a positive signal.
Key Dates
| Date | Description |
|---|---|
| 08/20/2024 | Purchase of 27,055 shares of common stock at a weighted average price of $12.97. |
| 08/21/2024 | Purchase of 12,945 shares of common stock at a weighted average price of $12.93. |
| 08/22/2024 | Date of signature for the SEC filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.